Pharmaron Beijing : CLOSURE OF REGISTER OF MEMBERS FOR THE FIRST H SHARES CLASS MEETING OF 2021
April 30, 2021 at 07:52 am EDT
Share
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
Pharmaron Beijing Co., Ltd.*
康龍化成（北京）新藥技術股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 3759)
CLOSURE OF REGISTER OF MEMBERS FOR
THE FIRST H SHARES CLASS MEETING OF 2021
The board of directors of Pharmaron Beijing Co., Ltd.* (康龍化成（北京）新藥技術股份有限公
司) (the "Company") hereby announces that, for the purpose of determining the H Shareholders entitled to attend and vote at the First H Shares Class Meeting of 2021 to be held on Friday, May 28, 2021 after the conclusion of the Annual General Meeting of 2020 to be held on Friday, May 28, 2021 at 2 p.m. or at any adjournment thereof (the "H Shares Class Meeting"), the register of members of the H Shares of the Company will be closed from Tuesday, May 25, 2021 to Friday, May 28, 2021 (both days inclusive), during which no transfer of H Shares will be registered. H Shareholders whose names appear on the register of members of the Company on Tuesday, May 25, 2021 shall be entitled to attend and vote at the H Shares Class Meeting. In order to attend the H Shares Class Meeting, H Shareholders should ensure that all transfer documents, accompanied by the relevant share certificates, are lodged with the Company's H Share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for H Shareholders) no later than 4:30 p.m. on Monday, May 24, 2021 to complete registration.
By order of the Board
Pharmaron Beijing Co., Ltd.*
康龍化成（北京）新藥技術股份有限公司
Dr. Lou Boliang
Chairman
Beijing, the PRC
April 30, 2021
As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Chen Pingjin, Mr. Hu Baifeng, Mr. Li Jiaqing and Mr. Zhou Hongbin as non-executive Directors; Mr. Dai Lixin, Ms. Chen Guoqin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.
For identification purposes only
Attachments
Original document
Permalink
Disclaimer
Pharmaron Beijing Co. Ltd. published this content on 30 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 April 2021 11:51:02 UTC.
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:
- laboratory services (61.3%);
- development and production of chemical processes and formulations (23.5%);
- clinical research services (12.8%);
- other (2.4%);
Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).
PHARMARON BEIJING CO., LTD. 
